Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
I-131-MIBG before high-dose chemotherapy and autologous stem cell transplantation for newly diagnosed high-risk neuroblastoma
jRCT2041190104Completed
- Sponsor
- FUJIFILM Toyama Chemical
- Start
- Jan 2020
- Modality
- Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics, Beta-minus Emitters → Radiopharmaceuticals, Gamma Emitters → Radiopharmaceuticals
- Countries
- 1
01
Overview
Open-label, single-arm trial of Iobenguane I-131 in neuroblastoma, sponsored by FUJIFILM Toyama Chemical. Primary endpoint: Dose dependent toxicity. Started Jan 2020; status: completed.
02
Drugs
Iobenguane I-131
03
Conditions
neuroblastoma
Beyond the preview
Go deeper on jRCT2041190104.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2041190104.